Bleakley Financial Group LLC Acquires Shares of 12,551 IQVIA Holdings Inc. $IQV

Bleakley Financial Group LLC bought a new position in IQVIA Holdings Inc. (NYSE:IQV) during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 12,551 shares of the medical research company’s stock, valued at approximately $2,384,000.

A number of other hedge funds have also bought and sold shares of the business. Versant Capital Management Inc grew its stake in IQVIA by 6.3% in the 3rd quarter. Versant Capital Management Inc now owns 899 shares of the medical research company’s stock valued at $171,000 after purchasing an additional 53 shares during the period. CVA Family Office LLC boosted its holdings in shares of IQVIA by 11.6% in the 3rd quarter. CVA Family Office LLC now owns 654 shares of the medical research company’s stock worth $124,000 after buying an additional 68 shares during the last quarter. UMB Bank n.a. grew its position in IQVIA by 11.0% during the third quarter. UMB Bank n.a. now owns 749 shares of the medical research company’s stock valued at $142,000 after buying an additional 74 shares during the period. E Fund Management Co. Ltd. increased its holdings in IQVIA by 3.7% during the second quarter. E Fund Management Co. Ltd. now owns 2,099 shares of the medical research company’s stock worth $331,000 after buying an additional 74 shares during the last quarter. Finally, Hartford Investment Management Co. raised its position in IQVIA by 0.8% in the third quarter. Hartford Investment Management Co. now owns 9,964 shares of the medical research company’s stock worth $1,893,000 after acquiring an additional 77 shares during the period. 89.62% of the stock is currently owned by institutional investors.

IQVIA Price Performance

Shares of NYSE:IQV opened at $162.08 on Tuesday. The company has a 50 day moving average of $216.37 and a 200 day moving average of $208.54. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.09. The stock has a market cap of $27.50 billion, a P/E ratio of 20.62, a P/E/G ratio of 1.60 and a beta of 1.37. IQVIA Holdings Inc. has a 12 month low of $134.65 and a 12 month high of $247.04.

IQVIA (NYSE:IQV) last announced its quarterly earnings results on Thursday, February 5th. The medical research company reported $3.42 EPS for the quarter, beating the consensus estimate of $3.40 by $0.02. The firm had revenue of $4.36 billion during the quarter, compared to the consensus estimate of $4.24 billion. IQVIA had a net margin of 8.34% and a return on equity of 30.50%. The business’s quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the firm earned $3.12 EPS. IQVIA has set its FY 2026 guidance at 12.550-12.850 EPS. As a group, sell-side analysts forecast that IQVIA Holdings Inc. will post 10.84 EPS for the current fiscal year.

Analyst Ratings Changes

Several brokerages have recently issued reports on IQV. Barclays decreased their price target on shares of IQVIA from $230.00 to $210.00 and set an “equal weight” rating for the company in a research note on Friday, February 6th. BMO Capital Markets set a $250.00 target price on IQVIA in a research report on Friday, February 6th. Morgan Stanley set a $240.00 price target on IQVIA in a research report on Wednesday, February 11th. Stifel Nicolaus decreased their price objective on IQVIA from $273.00 to $220.00 and set a “buy” rating for the company in a report on Friday, February 6th. Finally, JPMorgan Chase & Co. dropped their price objective on shares of IQVIA from $255.00 to $225.00 and set an “overweight” rating on the stock in a report on Friday, February 6th. Two investment analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating and four have issued a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $231.80.

IQVIA Profile

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real‑world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real‑world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.